A chimeric antigen receptor-based cellular safeguard mechanism for selective <i>in vivo</i> depletion of engineered T cells.

"Conflict of interest DB is co-founder of STAGE Cell Therapeutics GmbH now Juno Therapeutics, a Bristol-Myers Squibb Company and T Cell Factory B.V. now Kite/a Gilead Company. DB has a consulting contract with and receives sponsored research support from Juno Therapeutics/BMS. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."

"The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) SFB-TRR 338/1 2021 -452881907 (project A01), NIHCA 18029, and CA114536 (SRR). DB, LW and UJ also received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 116026. (T2EVOLVE)."